Evaluation of the efficasy of H. pylori eradication therapies using different PPI.

Evaluation of the efficasy of H. pylori eradication therapies using different PPI. - H. pylori eradication rate using different PPI.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014366

Enrollment

200

Registered

2014-07-01

Start date

2014-05-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastritis caused by H. pylori infection

Interventions

rabeprazole esomeprazole

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are infected with H. pylori and underwent upper GI endoscopy.

Exclusion criteria

Exclusion criteria: gastric cancer open peptic ulcers allergy to drugs past history of eradication therapy past history of gastric surgery administration of PPI or antibiotics

Design outcomes

Primary

Measure	Time frame
erdication rate	—

Secondary

Measure	Time frame
effects on dyspeptic symptoms adverse effects	—

Countries

Japan

Contacts

Public ContactTadashi Shimoyama

Hirosaki University Graduate School of Medicine Gastroenterology

tsimo-hki@umin.ac.jp0172-39-5053

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026